Type 2 diabetes and metabolic surgery: what should patients understand?

Why diabetes matters in bariatric assessment

The team may consider:

• duration of diabetes;
• HbA1c and current glucose control;
• insulin use;
• other diabetes medications;
• GLP-1 or GIP/GLP-1 treatment history;
• remaining pancreatic function where clinically relevant;
• obesity severity and visceral adiposity;
• fatty liver disease;
• cardiovascular and kidney health;
• ability to continue long-term follow-up.

How surgery can affect glucose metabolism

Weight loss is important, but metabolic effects may also involve changes in:

• insulin sensitivity;
• visceral and liver fat;
• gut hormone signalling;
• nutrient delivery through the intestine;
• hepatic glucose metabolism;
• appetite and energy intake.

Sleeve gastrectomy and gastric bypass

Both procedures may improve type 2 diabetes, but they differ in anatomy, reflux implications, nutritional requirements, and surgical complexity.

Procedure selection should not be based on diabetes alone.

What about GLP-1-based medication?

Medication and surgery do not always represent an either/or decision. Depending on the case, medication may be:

• the preferred first treatment;
• used before surgery;
• continued instead of surgery;
• used after surgery for selected patients with weight regain or inadequate response.

Remission is not the same as cure

Some patients may achieve diabetes remission after metabolic surgery. Diabetes can recur, and metabolic monitoring remains necessary. Medication changes must be made by the treating clinicians.

Information to prepare

• diabetes diagnosis date;
• recent HbA1c;
• current diabetes medication and doses;
• insulin use;
• previous GLP-1 treatment and response;
• kidney, cardiovascular, liver, and eye complications if known;
• weight history and previous weight-loss treatment.